# Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)

> **NCT00329745** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 8687 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Rotarix™
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00329745
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 8687 (ACTUAL)
- **Last updated:** 2016-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329745, "Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00329745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*